Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
A Top Contender in the Race for a NASH Drug Drops Out
03:02pm, Thursday, 23'rd Jul 2020
French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.
Genfit abandons late-stage trial of NASH drug elafibranor -
10:30am, Thursday, 23'rd Jul 2020
France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve
Genfit : renonce à traiter la NASH et cherche d'autres applications à l'Elafibranor | Zone bourse
08:39pm, Wednesday, 22'nd Jul 2020
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic stea
Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate
03:00pm, Tuesday, 21'st Jul 2020
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic, non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance, today announced the pub
Ascletis Pharma : Bridging Study in China Completed for NASH Drug Candidate ASC40 | MarketScreener
12:31am, Monday, 20'th Jul 2020Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
12:00am, Monday, 20'th Jul 2020
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Notable Insider Buys: Bed Bath & Beyond, Poseida Therapeutics And More
12:00am, Saturday, 18'th Jul 2020
Insider buying can be an encouraging signal for potential investors.
Insiders at biotechs took advantage of initial and secondary public offerings.
Notable insider purchases were...
Theratechnologies Inc. (THTX) Q2 2020 Earnings Call Transcript | The Motley Fool
02:30am, Thursday, 16'th Jul 2020
THTX earnings call for the period ending May 31, 2020.
Glympse Bio raises more than $46M in Series B round for biosensor technology
12:05pm, Wednesday, 15'th Jul 2020
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
12:00am, Wednesday, 15'th Jul 2020
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
